{# max-image-preview:large is what makes an article eligible for the big-image card in Google Discover — without it Google may only show a thumbnail. #} {# ── Google Preferred Sources ──────────────────────────────────────────── Readers who mark us as a preferred source get our fresh articles prioritised in Top Stories, Discover and Google News. Only domain- and subdomain-level sites are eligible — blog.alfafinder.com qualifies, a /news/ subdirectory would not. #}

Auro Laboratories — Latest News

Every announcement Auro Laboratories has filed with the exchanges that we have reported, newest first. Each story links the original filing.

NSE: AUROLAB BSE: 530233 Pharmaceuticals & Biotechnology 2 stories

Price

₹249.05

Market Cap

₹155.22

Revenue TTM

₹28.40

P/E (TTM)

52.51×

Sector 40.81×

Reference data from Trendlyne, as of the most recent story. Not a valuation or a recommendation.

Regulatory Approval · 2
Regulatory Approval

Auro Laboratories Secures EDQM Approval for Metformin Hydrochloride Facility at Tarapur

Auro Laboratories Ltd receives EDQM Attestation of Inspection for its MIDC Tarapur facility, confirming EU GMP compliance for Metformin Hydrochloride…
Regulatory Approval

Auro Laboratories Secures Swissmedic GMP Compliance for Tarapur Plant; Revenue Up 207%

Auro Laboratories Ltd (530233) secures Swissmedic GMP certification for its Tarapur unit, aligning with EU-Switzerland standards for therapeutic prod…

Track Auro Laboratories in real time

ALFA Finder watches NSE & BSE filings 24/7 and alerts you the moment Auro Laboratories files something material.

Start Free — 15-day trial
{# ── Promo popup — fires 5s after first page load per session. NEVER fires for visitors arriving from a search engine: a full-viewport overlay on a news article is an intrusive interstitial, and Google News policy is explicit that promotional material must not exceed the content. Direct, social and referral traffic still sees it. ─────────── #}